Construction of targeted 10B delivery agents and their uptake in gastric and pancreatic cancer cells

Frontiers in Oncology

Oncology

Lele Miao¹  Zhengchao Zhang¹  Jiaxing Zhang¹  Muzhou Teng¹  Song Wang¹  Futian Tang¹  Yumin Li¹ 

[1] Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China;Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China;

关键词: boron neutron capture therapy (BNCT);    boron delivery agent;    tumor;    selectivity;    solubility;   

DOI  :  10.3389/fonc.2023.1105472

 received in 2022-11-22, accepted in 2023-01-30,  发布年份 2023

来源: Frontiers

【 摘 要 】

Boron Neutron Capture Therapy (BNCT) is a new binary radiation therapy for tumor tissue, which kills tumor cells with neutron capture reaction. Boron neutron capture therapy has become a technical means for glioma, melanoma, and other diseases has been included in the clinical backup program. However, BNCT is faced with the key problem of developing and innovating more efficient boron delivery agents to solve the targeting and selectivity. We constructed a tyrosine kinase inhibitor-L-p-boronophenylalanine (TKI-BPA) molecule, aiming to improve the selectivity of boron delivery agents by conjugating targeted drugs while increasing the molecular solubility by adding hydrophilic groups. It shows excellent selectivity in differential uptake of cells, and its solubility is more than 6 times higher than BPA, leading to the saving of boron delivery agents. This modification method is effective for improving the efficiency of the boron delivery agent and is expected to become a potential alternative with high clinical application value.

【 授权许可】

Unknown   
Copyright © 2023 Wang, Zhang, Miao, Zhang, Tang, Teng and Li